Skip to main content
Equibles
CYTK logo

CYTK · Cytokinetics Inc · Investor Relations

Track CYTK — free

Use CYTK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CYTK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$56.13 -0.03 (-0.05%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$7.82B
Shares
139.30M
Volume · Nov 13 1.01M Avg daily vol (3M) 1.99M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-16 10:40 UTC UBS Global Biopharma Conference 2026 Conference
2026-11-17 11:00 UTC Jefferies Global Healthcare Conference Conference
2026-11-30 20:00 UTC 9th Annual Evercore Healthcare Conference Conference

Recent news

Date Headline
2026-11-10 MYQORZO® (aficamten) Receives ASMR III Rating from the HAS (French National Authority for Health) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy in Adults
2026-11-09 Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
2026-11-04 Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-03 Cytokinetics to Participate in November Investor Conferences
2026-11-02 Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
2026-10-21 Cytokinetics to Announce Third Quarter Results on November 4, 2026
2026-10-19 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-19 Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-10-12 Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
2026-10-02 Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
2026-09-30 Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-09-17 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-14 Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
2026-09-02 Cytokinetics to Participate in September Investor Conferences
2026-08-29 Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
2026-08-28 Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
2026-08-20 Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
2026-08-18 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-30 Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
2026-07-23 Cytokinetics to Announce Second Quarter Results on August 6, 2026
2026-07-17 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-07 Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
2026-06-17 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-08 Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Past events

Date Event Type
2026-11-10 Stifel 2026 Healthcare Conference Conference
2026-11-04 Cytokinetics Q3 2026 Earnings Conference Call Earnings call
2026-09-23 Bernstein 3rd Annual Healthcare Forum Webcast
2026-09-14 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-10 Cantor Global Healthcare Conference 2026 Conference
2026-09-09 Citi 2026 BioPharma Back to School Conference Conference
2026-08-28 ACACIA-HCM: Investor Event at ESC 2026 Event
2026-08-06 Cytokinetics Q2 2026 Earnings Conference Call Earnings call
2026-06-08 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-06-03 2026 Jefferies Global Healthcare Conference Conference
2026-05-19 2026 RBC Capital Markets Global Healthcare Conference Conference
2026-05-05 Cytokinetics Q1 2026 Earnings Conference Call Earnings call
2026-05-05 ACACIA-HCM Topline Results Earnings call
2026-04-13 25th Annual Needham Virtual Healthcare Conference Conference
2026-03-11 Barclays 28th Annual Global Healthcare Conference Conference
2026-03-11 2026 Jefferies Biotech on the Beach Summit Conference
2026-03-10 Citizens 2026 Life Sciences Conference Conference
2026-03-09 Leerink Partners Global Healthcare Conference Conference
2026-03-09 Leerink 2026 Global Healthcare Conference Conference
2026-02-24 Cytokinetics Q4 2025 Earnings Conference Call Earnings call
2026-01-12 J.P. Morgan 2026 Healthcare Conference Conference
2026-01-12 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-19 FDA Approval of MYQORZO (aficamten) Event
2025-11-17 Jefferies Global Healthcare Conference Conference
2025-11-11 Stifel 2025 Healthcare Conference Conference

Source: https://ir.cytokinetics.com/

Key facts CIK 1061983 CUSIP 23282W605 13F (30d) 369 filings 332 filers Visit website Investor relations